In a groundbreaking multi-country observational study published in The Lancet, researchers have observed a remarkable shift in the cardiovascular health landscape among adults with obesity in several high-income nations over the last three decades. This comprehensive analysis, encompassing almost one million participants from 110 health datasets collected between 1990 and 2024, reveals that adults over 40 years old living with obesity now exhibit blood pressure and unhealthy cholesterol levels comparable to, or even healthier than, their counterparts with normal body mass index (BMI). This surprising convergence represents a significant departure from historical trends and underscores the profound impact of cardiovascular medications on managing obesity-related metabolic risk factors.
Obesity, a metabolic disorder characterized by excessive adiposity, is well-known to elevate blood pressure and disrupt lipid metabolism, particularly by increasing levels of non-high-density lipoprotein (non-HDL) cholesterol. Non-HDL cholesterol encompasses all atherogenic lipoproteins, including LDL and VLDL particles, which contribute to the development of atherosclerosis and increase the risk of cardiovascular events such as myocardial infarction, stroke, and heart failure. In the 1990s, these perturbations in lipid and pressure parameters were markedly elevated in individuals with obesity compared to those with normal BMI, constituting well-documented cardiovascular risk.
The new study, spearheaded by research teams from the School of Public Health at Imperial College London, interrogated temporal trends in these biomarkers across seven economically developed countries: England, the United States, Japan, South Korea, Taiwan, Thailand, and Finland. Their findings elucidate a steep decline in both blood pressure and non-HDL cholesterol levels among middle-aged and older adults (aged 40–79) with overweight and obesity, contributing to the attenuation or near elimination of the metabolic disparity relative to normal BMI groups. Notably, England and the US demonstrated the most pronounced trend, with some older adults exhibiting healthier cardiovascular risk profiles despite elevated BMI.
Central to this epidemiological transformation is the escalating use of pharmaceutical interventions targeting dyslipidemia and hypertension. Statins, the cornerstone of cholesterol-lowering therapy, alongside antihypertensive agents, have become increasingly prescribed—especially for individuals with obesity who are inherently at elevated risk. The study highlights that by the early 2020s, an estimated 70–72% of older men with severe obesity (BMI ≥35) in these countries were receiving such medications, contrasted with 40–48% among normal BMI peers. This enhanced pharmacological engagement effectively modulates atherogenic lipid fractions and systemic vascular resistance, thereby blunting metabolic detriments conventionally attributed to elevated adiposity.
Despite this cardiovascular risk factor convergence among older adults with high BMI, the same pattern does not extend to younger populations under 40 years of age. The investigation underscores persistent gaps in blood pressure and cholesterol measures between obese and normal BMI younger adults, plausibly attributable to lower medication utilization in this demographic. This finding accentuates the notion that pharmacotherapy is the primary driver of risk equalization seen in older cohorts, while younger adults remain vulnerable to obesity-induced cardiovascular morbidity in the absence of intensive intervention.
Experts involved in the study emphasize the dual-edged nature of these results. On one hand, effective medical management represents a public health triumph, showcasing how systematic treatment of risk factors can neutralize some cardiovascular consequences of obesity across aging populations in affluent societies. On the other, the persistent metabolic and systemic risks inherent in obesity, including the heightened probability of diabetes mellitus, renal dysfunction, hepatic steatosis, and oncogenic processes, remain urgent clinical challenges that medication alone cannot resolve.
Importantly, the study also draws attention to the differential national contexts influencing these trends. While England, the USA, Japan, South Korea, and Finland manifested clear and consistent convergence in metabolic risk profiles among obesity strata, countries like Taiwan and Thailand exhibited less uniform patterns. These discrepancies may reflect variations in healthcare infrastructure, medication accessibility, public health policies, and cultural practices governing health-seeking behaviors.
From a mechanistic perspective, the pharmacodynamics of statins and antihypertensives bear significant relevance to the observed epidemiology. Statins function by inhibiting HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis, thereby reducing circulating LDL and non-HDL cholesterol fractions. Concurrently, antihypertensive drugs—ranging from ACE inhibitors and angiotensin receptor blockers to calcium channel blockers and diuretics—attenuate systemic vascular resistance and modulate neurohormonal pathways. This multi-modal approach effectively mitigates endothelial dysfunction, oxidative stress, and vascular inflammation, central pathophysiological facets of obesity-driven cardiovascular disease.
Furthermore, these findings emerge amidst an expanding therapeutic landscape where weight-loss pharmacotherapies gain prominence. The data provide a crucial baseline understanding of cardiovascular risk profiles in populations likely to receive such treatments, facilitating integrative healthcare strategies that combine weight management with aggressive risk factor control. Clinicians and policymakers can leverage this evidence to optimize resource allocation and treatment paradigms, stressing early intervention to preempt long-term metabolic sequelae.
However, researchers caution that this study’s scope is confined to high-income countries with relatively advanced healthcare systems and broad access to medications, limiting global generalizability. In low- and middle-income countries, where barriers to cardiovascular risk management persist, obesity may continue to confer disproportionate metabolic and cardiovascular burdens. Additionally, the investigation lacked granular data on medication dosing regimens and compliance, factors critical to fully elucidate treatment efficacy and population-level outcomes.
The study’s implications extend beyond epidemiology, prompting a re-examination of obesity-associated cardiovascular risk frameworks. As Dr. Yuan Lu from Yale School of Medicine notes, obesity-related risk factors embody a complex interplay of biological, healthcare access, and systemic intervention timing elements. The mere convergence of blood pressure and cholesterol levels should not be misconstrued as an elimination of risk but rather a call to integrate prevention strategies encompassing lifestyle modification, early screening, and comprehensive, multifaceted treatment approaches.
In summation, this landmark study advances our understanding of how medical treatment has reshaped the metabolic phenotype of obesity in affluent societies. It highlights an evolving public health narrative where pharmacological advances meaningfully rebalance obesity-driven cardiovascular risk, particularly in older adults, while underscoring the need for continued vigilance and innovation to address residual and age-specific vulnerabilities tied to excess adiposity. This nuanced perspective serves as a clarion call for sustained investment in preventive medicine, equitable healthcare access, and translational research harnessing the full therapeutic arsenal against the multifarious consequences of obesity.
Subject of Research: People
Article Title: Metabolic traits in obesity and normal BMI in industrialised countries: a multi-country analysis of national population-based studies
News Publication Date: 1-Jul-2026
Web References: http://dx.doi.org/10.1016/S0140-6736(26)00758-0
References: N/A
Image Credits: N/A
Keywords: Obesity, Blood pressure, Cholesterol, Cardiovascular risk, Statins, Antihypertensive medication, Metabolic disorders, Non-HDL cholesterol, Pharmacological treatment, Epidemiology
